AWM
BTAI icon

AllSquare Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

AllSquare Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13
Closed -$3K – 501
2022
Q2 		$3K Buy
+13
New +$2.73K ﹤0.01% 442
2020
Q4 		– Sell
-63
Closed -$43K – 457
2020
Q3 		$43K Buy
+63
New +$47.3K 0.03% 207

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

AllSquare Wealth Management's BTAI Position: Q3 2025 in Review

AllSquare Wealth Management held its BioXcel Therapeutics (BTAI) position steady in Q3 2025 at 175 shares worth $448. The position accounts for ﹤0.01% of the portfolio, ranked #504.

AllSquare Wealth Management first reported a position in BTAI in Q1 2019 and has held it in 25 quarters since. The position peaked at $254K in Q4 2020. 35 funds tracked by Wall St. Rank hold BTAI as of Q3 2025.

  • AllSquare Wealth Management held 175 shares of BioXcel Therapeutics worth $448 as of Q3 2025.
  • AllSquare Wealth Management left its BioXcel Therapeutics share count unchanged in Q3 2025.
  • BioXcel Therapeutics made up ﹤0.01% of AllSquare Wealth Management's portfolio in Q3 2025, its #504 holding.
  • AllSquare Wealth Management first reported a position in BioXcel Therapeutics in Q1 2019 and has held it in 25 quarters since.
  • AllSquare Wealth Management's BioXcel Therapeutics position peaked at $254K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2025.

Based on AllSquare Wealth Management's 13F filing for Q3 2025, filed 12 Jan 2026.